Research Square
February 25, 2026
Sean M. Viña
Abstract While prior research links psychedelic use to improved psychological outcomes, less is known about whether psychedelic exposure relates to engagement with formal mental health care when treatment is recognized as needed. Using pooled data from the National Survey on Drug Use and Health (2008–2019), this study examines whether lifetime psychedelic use is associated with missed needed...
February 24, 2026
Momoko Ishii, Mark Zervas
S elective S erotonin R euptake I nhibitors (SSRIs) and two psychedelics, Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine), and MDMA (3,4-Methylenedioxymethamphetamine) act on serotonergic-related neural circuits and function as serotonin modulators. All three molecules are either currently used or proposed as novel therapeutic modalities to treat P ost- T raumatic S tress D isorder (PTSD)....
Translation The University of Toledo Journal of Medical Sciences
February 17, 2026
Amy Hooper, Evelyn K. Lambe
MDMA-assisted psychotherapy has emerged as a promising treatment for post-traumatic stress disorder (PTSD), particularly in individuals unresponsive to conventional interventions such as SSRIs and trauma-focused cognitive behavioral therapy. As recent clinical trials report durable symptom remission, ongoing debate surrounds the mechanisms underlying its therapeutic effects. This review...
Journal of Forensic Sciences
February 12, 2026
Thomas Sheehan, Hilary J Hamnett, Sarah G. G. Russell et al.
3,4-Methylenedioxymethamphetamine (MDMA) or "ecstasy," is a commonly used drug worldwide, including in New Zealand, where 4.8% of the population aged 15 years or over reported using it in a 2023/2024 survey. This study provides additional insights on MDMA prevalence data in New Zealand by reporting toxicology data from Coronial and driving under the influence of drugs (DUID) cases positive for...
Br J Psychiatry
February 10, 2026
Tor-Morten Kvam, Ivar W Goksøyr, Justyna Rog et al.
An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Scientific Reports
February 10, 2026
Michelle Olofsson, Kasim Acar, Otto Simonsson et al.
Recent research has highlighted the potential of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for the treatment of post-traumatic stress disorder and other trauma-related psychiatric conditions. However, less is known about the effects of MDMA use on psychological well-being in populations with trauma histories outside of clinical contexts. In the present study, we assessed...
Behavioural Brain Research
February 10, 2026
Kristin A. Felsch, Jessica A. Siegel
3,4-methylenedioxymethamphetamine (MDMA) is a psychomotor stimulant drug. While much research has examined the effects of MDMA in adults, relatively little research has examined the effects in adolescents. Adolescence is a unique period of brain development, and the effects of MDMA may differ in adolescents compared to adults. In this review, we summarize the literature on the effects of acute...
International Journal of Electrochemical Science
February 9, 2026
Anne Felim, Anne Neudörffer, François P. Monnet et al.
A straightforward one-pot electrochemical synthesis of bis-catechol-thioether metabolites of MDMA (ecstasy), 2,5-bis(glutathion-S-yl)-N-methyl-α-methyldopamine and 2,5-bis(N-acetylcystein-S-yl)-N-methyl-α-methyldopamine, in acceptable yields and high degree of purity (99%), is described under environmentally friendly conditions. The undeniable benefits of this method, which uses...
Pharmacopsychiatry
February 5, 2026
Tianyi Xu, Sabrina Wong, Gia Han Le et al.
Serotonergic psychedelics, such as lysergic acid diethylamide, and psilocybin, and the entactogen 3,4-methylenedioxymethamphetamine exhibit agonist activity at the 5-hydroxytryptamine 2B receptor, a signalling pathway known to mechanistically mediate drug-induced valvular heart disease. This systematic review evaluates whether chronic or repeated use of psychedelics and...
Biological Psychiatry
February 3, 2026
Mehmet Bostancıklıoğlu, Davut Sinan Kaplan, Ramazan Bal et al.
Psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) produce rapid, enduring therapeutic effects in post-traumatic stress disorder (PTSD); however, the underlying cellular mechanisms remain incompletely understood. This study investigated whether adult myelin plasticity contributes to the therapeutic actions of psilocybin and MDMA in a rat model of contextual fear conditioning. Adult male...
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
February 2, 2026
Maya C Gaines-Smith, Justin M Silverman, Michael Fiorillo et al.
3 citations
The psychoactive entactogen 3,4-methylenedioxymethamphetamine (MDMA), widely known as a recreational drug, is gaining renewed attention as a potential psychotherapeutic adjunct for treatment-resistant psychiatric disorders, yet its neurobiological mechanisms - particularly those related to its stereoisomers and sex-specific effects - remain poorly understood. Here, we report stereoselective and...
Journal of Affective Disorders
February 2, 2026
Alene Sze Jing Yong, Aimee Freeburn, Suzie Bratuskins et al.
Australia recently became the first country to reschedule methylenedioxymethamphetamine (MDMA) to permit authorized prescribing for post-traumatic stress disorder (PTSD) outside of clinical trials. This study explored the direct experience of Australian clinicians, researchers, and patients regarding the use of MDMA-assisted psychotherapy (MDMA-AP) for PTSD to inform guideline development....
Psychopharmacology
February 1, 2026
Ana Deutsch, Connor J Haggarty, Gavin N Petrie et al.
1 citation
Stimulant drugs such as methamphetamine (MA) and 3,4-methylenedioxymethamphetamine (MDMA) can impact neurobiological systems implicated in stress, reward processing, and drug use. Although recent preclinical evidence implicates the endocannabinoid (eCB) system in these processes, little is known about the acute effects of stimulants on eCB levels in humans. The aim of the present study was to...
Pharmacology, biochemistry, and behavior
February 1, 2026
Daniel A Palacios-Lagunas, Juan C Hernández-mondragón, Kjell Fuxé et al.
1 citation
The promotion of prosocial behavior is a remarkable MDMA property. Such an effect is rather uncommon among other psychoactive substances and has been proposed to be of relevance for the potential therapeutic utility of MDMA. We aim to expand our knowledge of the prosocial effects of MDMA, considering sex and housing conditions as extra variables. To this end, housed individually or...
Neurologic Clinics
February 1, 2026
Mina Ansari, Sophie I Elliott, Sophie E Holmes et al.
1 citation
The development of novel, rapid-acting treatments and the resurgence of interest in the therapeutic potential of psychedelic-like compounds has stimulated excitement and enthusiasm within the pharmaceutical industry, and provided new hope for millions of individuals suffering with mental illness such as major depressive disorder and post-traumatic stress disorder. This review summarizes the...